Responses
Clinical/translational cancer immunotherapy
Original research
Risk-adapted chemoimmunotherapy using brentuximab vedotin and rituximab in children, adolescents, and young adults with newly diagnosed Hodgkin’s lymphoma: a phase II, non-randomized controlled trial
Compose a Response to This Article
Other responses
No responses have been published for this article.